Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15163196rdf:typepubmed:Citationlld:pubmed
pubmed-article:15163196lifeskim:mentionsumls-concept:C0005682lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0001480lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0205359lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0439799lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C1880355lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C1144476lld:lifeskim
pubmed-article:15163196lifeskim:mentionsumls-concept:C1140999lld:lifeskim
pubmed-article:15163196pubmed:issue12lld:pubmed
pubmed-article:15163196pubmed:dateCreated2004-5-27lld:pubmed
pubmed-article:15163196pubmed:abstractTextStructure-activity relationships were investigated on a novel series of sulfonyldihydropyridine-containing K(ATP) openers. Ring sizes, absolute stereochemistry, and aromatic substitution were evaluated for K(ATP) activity in guinea pig bladder cells using a fluorescence-based membrane potential assay and in a pig bladder strip assay. The inhibition of spontaneous bladder contractions in vitro was also examined for a select group of compounds. All compounds studied showed greater potency to inhibit spontaneous bladder contractions relative to their potencies to inhibit contractions elicited by electrical stimulation. In an anesthetized pig model of myogenic bladder overactivity, compound 14 and (-)-cromakalim 1 were found to inhibit spontaneous bladder contractions in vivo at plasma concentrations lower than those that affected hemodynamic parameters. Compound 14 showed approximately 5-fold greater selectivity than 1 in vivo and supports the concept that bladder-selective K(ATP) channel openers may have utility in the treatment of overactive bladder.lld:pubmed
pubmed-article:15163196pubmed:languageenglld:pubmed
pubmed-article:15163196pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15163196pubmed:citationSubsetIMlld:pubmed
pubmed-article:15163196pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15163196pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15163196pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15163196pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15163196pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15163196pubmed:statusMEDLINElld:pubmed
pubmed-article:15163196pubmed:monthJunlld:pubmed
pubmed-article:15163196pubmed:issn0022-2623lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:BELJ KJKlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:ItôHHlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:HolladayMark...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:BucknerSteven...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:BruneMichael...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:MilicicIvanIlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:FitzgeraldMic...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:CoghlanMichae...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:DazaAnthony...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:Gopalakrishna...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:WhiteakerKris...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:DrizinIreneIlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:SullivanJames...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:CarrollWillia...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:KymPhilip RPRlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:BrioniJorge...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:AltenbachRobe...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:TangRuiRlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:FeyThomas ATAlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:CassidyChrist...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:KingLinda LLLlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:KortMichael...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:TurnerSean...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:GreggRobert...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:ZhangHenryHlld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:HenryRodger...lld:pubmed
pubmed-article:15163196pubmed:authorpubmed-author:ChenYiyuanYlld:pubmed
pubmed-article:15163196pubmed:issnTypePrintlld:pubmed
pubmed-article:15163196pubmed:day3lld:pubmed
pubmed-article:15163196pubmed:volume47lld:pubmed
pubmed-article:15163196pubmed:ownerNLMlld:pubmed
pubmed-article:15163196pubmed:authorsCompleteYlld:pubmed
pubmed-article:15163196pubmed:pagination3163-79lld:pubmed
pubmed-article:15163196pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:meshHeadingpubmed-meshheading:15163196...lld:pubmed
pubmed-article:15163196pubmed:year2004lld:pubmed
pubmed-article:15163196pubmed:articleTitleSynthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions.lld:pubmed
pubmed-article:15163196pubmed:affiliationAbbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL 60064-6101, USA. william.a.carroll@abbott.comlld:pubmed
pubmed-article:15163196pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15163196pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:15163196lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15163196lld:pubmed